Details

Autor(en) / Beteiligte

• Pandina, Gahan J
• Busner, Joan
• Kempf, Lucas
• Fallon, Joan
• Alphs, Larry D
• Acosta, Maria T
• Berger, Anna-Karin
• Day, Simon
• Dunn, Judith
• Villalta-Gil, Victoria
• Grabb, Margaret C
• Horrigan, Joseph P
• Jacobson, William
• Kando, Judith C
• Macek, Thomas A
• Singh, Manpreet K
• Stanford, Arielle D
• Domingo, Silvia Zaragoza

Titel

Ensuring Stakeholder Feedback in the Design and Conduct of Clinical Trials for Rare Diseases: ISCTM Position Paper of the Orphan Disease Working Group

Ist Teil von

• Innovations in clinical neuroscience, 2024-01, Vol.21 (1-3), p.52-60

Ort / Verlag

United States

Erscheinungsjahr

2024

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• The 1983 Orphan Drug Act in the United States (US) changed the landscape for development of therapeutics for rare or orphan diseases, which collectively affect approximately 300 million people worldwide, half of whom are children. The act has undoubtedly accelerated drug development for orphan diseases, with over 6,400 orphan drug applications submitted to the US Food and Drug Administration (FDA) from 1983 to 2023, including 350 drugs approved for over 420 indications. Drug development in this population is a global and collaborative endeavor. This position paper of the International Society for Central Nervous System Clinical Trials and Methodology (ISCTM) describes some potential best practices for the involvement of key stakeholder feedback in the drug development process. Stakeholders include advocacy groups, patients and caregivers with lived experience, public and private research institutions (including academia and pharmaceutical companies), treating clinicians, and funders (including the government and independent foundations). The authors articulate the challenges of drug development in orphan diseases and propose methods to address them. Challenges range from the poor understanding of disease history to development of endpoints, targets, and clinical trials designs, to finding solutions to competing research priorities by involved parties.